=The Medicines Co (MDCO) : FDA approves Vabomere

The Medicines Co confirms FDA approval of VABOMERE for injection for the treatment of adult patients with complicated urinary tract infections
The co expects that VABOMERE will be available in the fourth quarter of 2017. The FDA approval of VABOMERE triggered a $40 million milestone payment obligation to the former securityholders of Rempex Pharmaceuticals, Inc., which the co acquired in December 2013.